Edaravone Administration Duration in Acute Ischemic Stroke
Edaravone is NOT recommended for acute ischemic stroke treatment based on current major stroke guidelines, as no neuroprotective agent has been established as beneficial for this indication.
Critical Context: Edaravone's Approved Indication
The FDA-approved indication for edaravone is amyotrophic lateral sclerosis (ALS), not stroke 1. The approved ALS dosing regimen consists of:
- Initial cycle: 60 mg IV daily for 14 days, followed by 14-day drug-free period
- Subsequent cycles: 60 mg IV daily for 10 days out of each 14-day period, followed by 14-day drug-free periods
Guideline Position on Neuroprotective Agents in Stroke
Major stroke guidelines consistently state that no neuroprotective medication has proven useful for acute ischemic stroke treatment 2. The 2003 and 2013 AHA/ASA guidelines explicitly note that medications with putative neuroprotective effects have not been shown beneficial for stroke patients. The 2018 AHA/ASA guidelines 3 do not recommend edaravone for acute ischemic stroke.
Research Evidence on Edaravone in Stroke
While recent research has explored edaravone dexborneol (a combination formulation, not standard edaravone) in stroke:
- The TASTE-2 trial 4 studied edaravone dexborneol (37.5 mg twice daily for 10-14 days) in patients undergoing thrombectomy, showing marginal benefit (55.0% vs 49.6% functional independence, P=0.05)
- The TASTE trial 5 used 14-day infusion of edaravone dexborneol versus edaravone alone
- A 2026 study 6 examined edaravone in large vessel occlusion patients not receiving thrombolysis/thrombectomy, showing radiological but not clinical improvement
Important distinction: These studies used edaravone dexborneol (a different compound combining edaravone with borneol), not standard edaravone monotherapy, and results remain exploratory 7, 8.
Clinical Recommendation
If edaravone were to be used off-label in stroke (which is not guideline-supported), the duration studied in research protocols is 10-14 days of twice-daily administration. However, this represents investigational use only.
Standard acute stroke care should prioritize:
- IV alteplase within 3-4.5 hours if eligible 9, 3
- Mechanical thrombectomy for large vessel occlusion within 24 hours 3
- Aspirin 160-325 mg within 24-48 hours 10, 11, 3
Key Caveats
- Edaravone monotherapy lacks robust evidence for stroke
- Edaravone dexborneol (the studied formulation) is not FDA-approved for stroke in most countries
- The 2026 meta-analysis 8 suggests benefits should be "interpreted cautiously" pending larger trials
- Safety profile appears acceptable 12, but efficacy remains unproven for standard stroke care